GSK bribery scandal: Beijing tightens grip on multinationals in China

Drug firm among several being investigated as case highlights risks of operating in markets where corruption is the status quo The GlaxoSmithKline allegations have highlighted China's increasingly tight grip on international firms as they vie for a foothold in the burgeoning Chinese consumer markets. China-based divisions of international firms have found themselves in the target sights of government investigations. Last month, the National Development and Reform Commission announced an investig...